Question explored with the scientific record
Conversation so far
- 1 what are the recovery numbers and potential for Long covid in a 74 year old healthy male, numners worlwide + a private exchange
- 2 i know you have numbers somewhere about recovery length of time for the non hospitalized + a private exchange
- 3 what about long covid revoery for all ages after 8 months + a private exchange
- 4 what about recovery of thoe not hospitalized + a private exchange
- 5 is there anyting medicone can do?
Answered on this page ↓
is there anyting medicone can do?
The short version: medicine has almost nothing proven to offer for persistent post-COVID GI symptoms at 30 months, and the evidence retrieved does not contain a single treatment trial for this exact condition.
The evidence you retrieved is almost entirely about describing the problem, not solving it. The VA cohort study [3] and the Bronx study [1] document that GI symptoms persist for one to three years after infection, with hazard ratios between 1.18 and 1.54 for various outcomes. The systematic review [2] found persistent GI symptoms in 10.8% of infected people versus 4.9% of controls. But none of these studies tested a treatment. The one intervention study in the evidence is about feeding tube placement technique in ICU patients [4], which has nothing to do with an older adult at home with lingering gut symptoms.
The 2026 review on functional GI disorders in IBD [9] is the closest thing to a treatment framework, but it addresses inflammatory bowel disease, not post-COVID GI symptoms. It does describe approaches that might apply: testing for small intestinal bacterial overgrowth (SIBO), bile acid diarrhea, and pancreatic insufficiency, then treating those specifically. But this is extrapolation, not evidence for this population.
| What is known | What is not known |
|---|---|
| GI symptoms persist at 30 months [1, 3] | No treatment trial for post-COVID GI symptoms exists in this evidence |
| Risk is 18-54% higher than controls [1, 3] | No comparison of drug vs placebo for this condition |
| Mechanisms include dysbiosis and spike persistence | No tested protocol for gut restoration |
My call: the evidence retrieved does not support any specific medical intervention for persistent post-COVID GI symptoms at 30 months. The honest answer is that nobody has run the trials. Confidence: high that the evidence gap is real.
Sources examined 24
-
New-onset gastrointestinal disorders in COVID-19 patients 3.5 years post-infection in the inner-city population in the Bronx
This study investigates the incidence and risk factors of new gastrointestinal disorders in COVID-19 patients up to 3.5 years post-infection, revealing a higher incidence compared to matched controls.
DOI: 10.1038/s41598-024-83232-7 -
A Systematic Review of the Prevalence of Persistent Gastrointestinal Symptoms and Incidence of New Gastrointestinal Illness after Acute SARS-CoV-2 Infection
This is a systematic review synthesizing 45 observational studies (n ≈ 2.22 million) to estimate the prevalence of persistent gastrointestinal symptoms after acute SARS-CoV-2 infection and the incidence of new GI illnesses, finding a modest overall burden with substantial hetero…
DOI: 10.3390/v15081625 -
Long-term gastrointestinal outcomes of COVID-19
This large US Veterans Affairs cohort study quantified the long-term (1-year) risks and burdens of a broad set of post-acute gastrointestinal disorders after SARS-CoV-2 infection, revealing elevated risks even among non-hospitalized individuals and a gradient with acute infectio…
DOI: 10.1038/s41467-023-36223-7 -
The Effects of Endoscopy-Guided Nasojejunal Feeding Tube Placement in Post-COVID-19 ICU Patients: A Retrospective Study
A retrospective cohort study comparing endoscopy-guided nasojejunal feeding tube placement (ENFT) versus blind bedside placement (BNFT) in post-COVID-19 ICU patients, showing ENFT is associated with fewer long-term post-COVID complications and better gastrointestinal and cardiov…
DOI: 10.2147/ijgm.s523748 -
Headache characteristics in COVID-19 pandemic-a survey study
This study investigates the characteristics of headaches associated with COVID-19, revealing that bilateral, long-lasting headaches resistant to analgesics are more common in infected individuals, alongside symptoms like anosmia and gastrointestinal complaints.
DOI: 10.1186/s10194-020-01188-1 -
Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study
Outpatients with acute COVID-19 follow a pattern of symptom progression from systemic and upper respiratory symptoms to lower respiratory and gastrointestinal symptoms, with initial symptom severity strongly predicting how long symptoms last and persistent symptoms being common.
DOI: 10.1136/bmjopen-2020-044154 -
Impact of Gastrointestinal Symptoms on in-Hospital Outcomes and Long-Term Sequelae in Hospitalized COVID-19 Patients: A Prospective Cohort Study
A prospective cohort study of 246 hospitalized COVID-19 patients in Dhaka, Bangladesh found that those with gastrointestinal (GI) symptoms had better in-hospital oxygen requirements and higher rates of complete recovery, but similar ICU/ventilation and mortality rates and compar…
DOI: 10.11648/j.ijg.20240802.13 -
Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report
This case report discusses the successful use of tacrolimus as a bridging therapy for a 68-year-old patient with severe acute, cortisone-refractory ulcerative colitis and concurrent severe Covid-19 pneumonia.
DOI: 10.1186/s12876-022-02094-3 -
Involvement of gastrointestinal functional disorder in the management of inflammatory bowel disease
FGID-like symptoms commonly persist in IBD despite controlled inflammation, requiring a structured, multidisciplinary diagnostic approach and symptom-focused management beyond mucosal healing.
DOI: 10.1159/000551457 -
Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors
This multicenter study trained machine learning models on baseline clinical, laboratory, antibody, and viral load data from hospitalized COVID-19 patients (IMPACC cohort) to predict progression to long COVID (PASC), identifying low anti-Spike IgG and high viral load at admission…
DOI: 10.1038/s43856-025-01230-w -
Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method
During the COVID-19 period, gastric cancer patients undergoing laparoscopic radical gastrectomy had longer surgeries, more blood loss, and longer hospital stays, but similar short-term and long-term complication rates compared with those treated before the pandemic, with overall…
DOI: 10.1186/s12885-023-11441-w -
Author’s response to the letter “From correlation to causation: unraveling the role of long non-coding RNAs in COVID-19 pathogenesis”
This study investigates whether COVID-19 alters long noncoding RNA (lncRNA) expression in peripheral blood mononuclear cells (PBMCs) and evaluates host-based lncRNA biomarkers for screening COVID-19 using RT-qPCR and machine learning, with limited but supportive external validat…
DOI: 10.1186/s12985-025-02876-7 -
Risk factors for COVID-19 infection in people with 4th dose of bivalent mRNA vaccines in general medicine from October 2022 to February 2023
Among adults who received a fourth dose of bivalent mRNA vaccines, socio-health care workers and chronic diseases linked to immunosuppression significantly increased the risk of breakthrough COVID-19 infection, while older age suggested protection but was not statistically signi…
DOI: 10.17352/2455-5479.000198 -
Effects of BNT162b2 mRNA vaccine on COVID-19 infection and hospitalisation amongst older people: matched case control study for England
This study estimates the effectiveness of the BNT162b2 mRNA vaccine in reducing COVID-19 infections and hospitalizations among older adults in England by comparing vaccinated individuals aged 80-83 to slightly younger unvaccinated controls.
DOI: 10.1186/s12916-021-02149-4 -
The Impact of Long-Term Conditions and Comorbidity Patterns on COVID-19 Infection and Hospitalisation: A Cohort Study
Cardiovascular disease and complex comorbidity patterns in older English adults were linked to higher odds of COVID-19 infection, while undiagnosed diabetes increased hospitalisation risk and retinopathy predicted hospitalisation, underscoring the need for targeted screening and…
DOI: 10.1159/000531848 -
Impact of dementia on risks of COVID-19 infection and outcomes among older adults in Sweden
A nationwide, register-based Swedish study during the first COVID-19 wave shows that older adults with dementia had higher risks of COVID-19 infection and mortality than those without dementia, with dementia also linked to higher hospitalization risk in community-dwelling senior…
DOI: 10.1186/s12877-025-06576-3 -
COVID-19 vaccination lowers SARS-CoV-2 infection risk independent of diabetes, cancer and smoking in SHIP-COVID cohort, Northern Germany
This prospective cohort study in Northern Germany (SHIP-COVID) shows that SARS-CoV-2 infection risk decreases with increasing COVID-19 vaccine doses, with significant protection after three and four doses, and finds no evidence that diabetes, cancer, or smoking modify this prote…
DOI: 10.1038/s41598-025-22334-2 -
Epidemiological Shifts in Respiratory Virus Infections Among Older Adults (≥65 Years) Before and After the COVID-19 Pandemic: An 18-Year Retrospective Study in the Republic of Korea
An 18-year retrospective, hospital-based study in Korea analyzing respiratory virus infections in adults aged ≥65 to characterize testing participation, virus circulation, seasonality, and sex differences before, during, and after the COVID-19 pandemic across 15 viruses using mu…
DOI: 10.3390/microorganisms13102301 -
On tuberculosis and COVID-19 co-infection
This study reports the first cohort of patients with tuberculosis (TB) and COVID-19 co-infection, describes the timing of TB and COVID-19 diagnoses across multiple countries, notes higher mortality with older age and pre-existing comorbidities (while migrants without comorbiditi…
DOI: 10.1183/13993003.02328-2020 -
Trust in Governmental Health Communication on Covid-19
This study uses four waves of a representative German online panel to examine how trust in governmental Covid-19 health communication relates to partisanship and various vulnerability dimensions, finding lower trust among AfD voters, higher trust among older individuals and thos…
DOI: 10.47368/ejhc.2024.302 -
Characteristics and Pathophysiological Mechanisms of Stroke in COVID-19 Patients
COVID-19 infection combined with ischemic stroke is linked to higher mortality, with older age and coagulation abnormalities (elevated D-dimer and INR) predicting death.
DOI: 10.36472/msd.v11i1.1115 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY
A multicenter Turkish cohort of 569 hematologic malignancy patients with COVID-19 shows 29.3% all-cause in-hospital mortality, with older age, cardiac comorbidities, and continuing active cancer therapy during infection independently predicting death.
DOI: 10.4084/mjhid.2022.074 -
Liver transplant recipients infected with SARS‐CoV‐2 in the early postoperative period: Lessons from a single center in the epicenter of the pandemic
This study reports a case series of five liver transplant recipients who developed nosocomial COVID-19 in the early postoperative period, highlighting the negative impact of COVID-19 on postoperative outcomes, particularly in older patients with comorbidities.
DOI: 10.1111/tid.13418 -
New Insights Into the Comorbidity of Coronary Heart Disease and Depression
This 2019 Curr Probl Cardiol review synthesizes how coronary heart disease and depression co-occur, summarizes shared pathophysiological mechanisms (inflammation, HPA/autonomic dysfunction, endothelial and behavioral factors, gut microbiota, and endocrine/miRNA signaling), and d…
DOI: 10.1016/j.cpcardiol.2019.03.002